• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 419674 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413826790 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413826790 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Spectrum Pharmaceuticals on 1.2x Above-Average Volume (SPPI)

Published on Thu, 01/10/2013 - 14:13
By Peter Chu

Shares of Spectrum Pharmaceuticals are trading up 3.1% to $13.00 today on above average volume. Today's volume of 1.1 million shares tops the average 30-day volume of 918,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.

Potential upside of 70.8% exists for Spectrum Pharmaceuticals, based on a current level of $13.00 and analysts' average consensus price target of $22.20. The stock should discover initial support at its 200-day moving average (MA) of $12.20 and subsequent support at its 50-day MA of $11.29.

In the past 52 weeks, shares of Spectrum Pharmaceuticals have traded between a low of $9.31 and a high of $17.48 and are now at $13.00, which is 40% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.4%.

Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's satraplatin is an oral, anti-cancer drug. Spectrum's Elsamitrucin targets non-Hodgkin's lymphoma, and Neoquin is being studied in the treatment of superficial bladder cancer. Spectrum also has a pipeline of pre-clinical neurological drug candidates.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Fairchild Semiconductor International Ma...

Fairchild Semiconductor International (NYSE:FCS) is a company whose shares are active, ...

Stock Investors Bid Up Shares of Angiody...

One of today's stocks on the move is Angiodynamics (NASDAQ:ANGO), up 2.6% to $15.69. T ...

Royal Bank of Scotland Shares Climbing H...

One of today's notable stocks on the rise is Royal Bank of Scotland (NYSE:RBS), up 2.6% ...

Buyers Accumulate Shares of Lululemon At...

Lululemon Athletica (NASDAQ:LULU) is a company whose shares are active, trading 2.6% hi ...

Johnson Outdoors Makes a Move: Down 2.6%...

One of today's stocks on the move is Johnson Outdoors (NASDAQ:JOUT), down 2.6% to $26.6 ...

Shares of Vimicro International Receive ...

Vimicro International (NASDAQ:VIMC), a company whose shares are moving quickly, is trad ...

Shares of Medtronic Receive a Boost, Up ...

Up 2.7% to $63.64, Medtronic (NYSE:MDT), is one of today's notable movers. The Dow is ...

FreightCar America Shares Sinking Lower,...

FreightCar America (NASDAQ:RAIL) is one of today's biggest movers, down 2.7% to $31.08. ...